EQT completed the acquisition of Igenomix for $450m.

EQT completed the acquisition of Igenomix, a biotechnology company in women's health and reproductive genetics services for in vitro fertilization clinics for $450m. Financial terms were not disclosed. EQT will support Igenomix in its international growth thanks to its solid experience in the healthcare field, its global platform and its network of industrial consultants. "We are impressed by the trajectory of Igenomix and the results achieved by the management team. Igenomix is ​​a world leader in IVF genetic diagnostic services - a high growth segment - and focuses on quality, innovation leadership and customer service. These attributes fit perfectly with the investment philosophy of EQT. At EQT, we are looking forward to supporting Igenomix and its strong management team to continue contributing to its growth." Vesa Koskinen, EQT Partners Partner.